Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
$0.01
$0.00
▼
$0.56
$105K-9.0968,411 shs577 shs
Celularity, Inc. stock logo
CELU
Celularity
$0.71
+1.1%		$0.73
$0.56
▼
$4.31
$20.38M0.5444,048 shs30,129 shs
Evogene Ltd. stock logo
EVGN
Evogene
$0.65
-7.8%		$0.53
$0.37
▼
$1.50
$5.63M1.4958,211 shs6,349 shs
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
$3.81
$3.97
$3.19
▼
$21.40
$20.59M0.75449,191 shs30,362 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
0.00%0.00%-54.55%+2,400.00%-99.09%
Celularity, Inc. stock logo
CELU
Celularity
+1.98%-0.45%-5.43%-10.98%-78.32%
Evogene Ltd. stock logo
EVGN
Evogene
+10.79%+7.77%+36.82%-7.83%-42.11%
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
-1.30%-2.06%+7.63%-23.49%-47.08%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
$0.01
$0.00
▼
$0.56
$105K-9.0968,411 shs577 shs
Celularity, Inc. stock logo
CELU
Celularity
$0.71
+1.1%		$0.73
$0.56
▼
$4.31
$20.38M0.5444,048 shs30,129 shs
Evogene Ltd. stock logo
EVGN
Evogene
$0.65
-7.8%		$0.53
$0.37
▼
$1.50
$5.63M1.4958,211 shs6,349 shs
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
$3.81
$3.97
$3.19
▼
$21.40
$20.59M0.75449,191 shs30,362 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
0.00%0.00%-54.55%+2,400.00%-99.09%
Celularity, Inc. stock logo
CELU
Celularity
+1.98%-0.45%-5.43%-10.98%-78.32%
Evogene Ltd. stock logo
EVGN
Evogene
+10.79%+7.77%+36.82%-7.83%-42.11%
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
-1.30%-2.06%+7.63%-23.49%-47.08%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
1.00
SellN/AN/A
Celularity, Inc. stock logo
CELU
Celularity
2.00
Hold$6.00747.46% Upside
Evogene Ltd. stock logo
EVGN
Evogene
1.00
SellN/AN/A
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
2.00
Hold$21.00451.18% Upside

Current Analyst Ratings Breakdown

Latest EVGN, CARM, NEUP, and CELU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/5/2026
Celularity, Inc. stock logo
CELU
Celularity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/8/2026
Evogene Ltd. stock logo
EVGN
Evogene
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/6/2026
Celularity, Inc. stock logo
CELU
Celularity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/1/2026
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
5/15/2026
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral
(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$10.77M0.01N/AN/A($0.67) per share0.00
Celularity, Inc. stock logo
CELU
Celularity
$26.55M0.77N/AN/A($1.32) per share-0.54
Evogene Ltd. stock logo
EVGN
Evogene
$3.85M1.46N/AN/A$1.37 per share0.47
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
$15.65M1.31$0.15 per share24.77$10.11 per share0.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$60.48M$0.730.00N/AN/A-254.28%N/A-192.17%N/A
Celularity, Inc. stock logo
CELU
Celularity
-$91.72M-$3.33N/AN/AN/A-345.45%N/A-77.94%8/12/2026 (Estimated)
Evogene Ltd. stock logo
EVGN
Evogene
-$8.48M-$1.39N/AN/AN/A-638.12%-158.82%-80.37%8/18/2026 (Estimated)
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
-$370K-$11.06N/AN/AN/AN/A-76.93%-54.76%9/2/2026 (Estimated)

Latest EVGN, CARM, NEUP, and CELU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026Q4 2026
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
-$0.56N/AN/AN/AN/AN/A
8/18/2026Q2 2026
Evogene Ltd. stock logo
EVGN
Evogene
-$0.27N/AN/AN/A$0.33 millionN/A
5/16/2026Q1 2026
Evogene Ltd. stock logo
EVGN
Evogene
-$0.27-$0.60-$0.33-$0.60$0.35 million$0.33 million
5/15/2026Q3 2026
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
-$0.56-$0.09+$0.47-$0.09N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/AN/AN/AN/AN/A
Celularity, Inc. stock logo
CELU
Celularity
N/AN/AN/AN/AN/A
Evogene Ltd. stock logo
EVGN
Evogene
N/AN/AN/AN/AN/A
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/A
0.48
0.48
Celularity, Inc. stock logo
CELU
Celularity
N/A
0.15
0.15
Evogene Ltd. stock logo
EVGN
Evogene
N/A
2.79
2.76
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
N/A
14.31
14.31

Institutional Ownership

CompanyInstitutional Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
44.27%
Celularity, Inc. stock logo
CELU
Celularity
19.02%
Evogene Ltd. stock logo
EVGN
Evogene
10.40%
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
15.90%

Insider Ownership

CompanyInsider Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
6.90%
Celularity, Inc. stock logo
CELU
Celularity
17.30%
Evogene Ltd. stock logo
EVGN
Evogene
7.40%
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
2041.85 million38.91 millionNo Data
Celularity, Inc. stock logo
CELU
Celularity
22028.95 million23.94 millionOptionable
Evogene Ltd. stock logo
EVGN
Evogene
1408.72 million8.07 millionNo Data
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
N/A5.40 million5.32 millionN/A

Recent News About These Companies

Neuphoria Therapeutics Inc (NEUP)
August 8, 2026  |  investing.comhttps://www.investing.com/equities/bionomics-adr-financial-summary
The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAX
July 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/30/3336244/0/en/the-m-a-class-action-firm-encourages-hareholders-to-contact-monteverde-concerning-the-merger-nrim-neup-saft-and-rmax.html
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—PBCO, NEUP, SAFT, and PFLC
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334582/0/en/hareholder-alert-the-m-a-class-action-firm-launches-legal-inquiry-for-the-merger-pbco-neup-saft-and-pflc.html
NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders
July 24, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260724986821/en/neup-stock-alert-halper-sadeh-llc-is-investigating-whether-neuphoria-therapeutics-inc.-is-obtaining-a-fair-price-for-its-shareholders/
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)
July 24, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-neuphoria-therapeutics-inc-nasdaq-neup-302834210.html
Small cap movers: Scancell heads to Nasdaq as AIM's headcount falls to 612
July 24, 2026  |  msn.comhttps://www.msn.com/en-nz/news/other/small-cap-movers-scancell-heads-to-nasdaq-as-aims-headcount-falls-to-612/ar-AA28ANdj
Scancell to go public after winning reverse merger bid for troubled Neuphoria
July 24, 2026  |  fiercebiotech.comF
Scancell and Neuphoria agree all-share merger supported by up to US$89 million financing
July 24, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/scancell-neuphoria-agree-share-merger-072930948.html
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3331958/0/en/scancell-and-neuphoria-therapeutics-announce-merger-agreement-and-financing.html
Neuphoria Therapeutics Stock Dividends | NASDAQ:NEUP | Benzinga
July 11, 2026  |  benzinga.comhttps://www.benzinga.com/quote/NEUP/dividends
Merck axes Alzheimer’s study, adding to partner Neuphoria’s mounting woes
July 3, 2026  |  biospace.comB
Merck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelms
July 1, 2026  |  fiercebiotech.comF
MRK, NEUP stocks drop as Merck scraps another Alzheimer’s drug trial under Neuphoria partnership
July 1, 2026  |  msn.comhttps://www.msn.com/en-in/health/other/mrk-neup-stocks-drop-as-merck-scraps-another-alzheimer-s-drug-trial-under-neuphoria-partnership/ar-AA270ahB
Neuphoria Therapeutics Inc. Common Stock
June 27, 2026  |  fxempire.comF
Neuphoria Therapeutics in Talks to Be Acquired by Scancell Holdings
June 27, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/neuphoria-therapeutics-in-talks-to-be-acquired-by-scancell-holdings-be7105bd
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
June 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/26/3318455/0/en/neuphoria-responds-to-the-announcement-made-by-london-listed-scancell-holdings-plc.html
HC Wainwright & Co. downgrades Neuphoria Therapeutics (NEUP)
May 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/hc-wainwright-co-downgrades-neuphoria-therapeutics-neup/ar-AA23khdg
Neuphoria Therapeutics (NEUP) price target increased by 38.22% to 13.77
May 14, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/neuphoria-therapeutics-neup-price-target-increased-by-3822-to-1377/ar-AA23aODg
Here's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Situation
February 19, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/heres-why-were-not-concerned-110016072.html
Neuphoria Therapeutics (NEUP) price target decreased by 32.33% to 9.96
December 22, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/neuphoria-therapeutics-neup-price-target-decreased-by-3233-to-996/ar-AA1SNzuz

New MarketBeat Followers Over Time

Media Sentiment Over Time

Carisma Therapeutics stock logo

Carisma Therapeutics NASDAQ:CARM

$0.0025 0.00 (0.00%)
As of 08/11/2026 10:29 AM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Celularity stock logo

Celularity NASDAQ:CELU

$0.71 +0.01 (+1.11%)
As of 09:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Evogene stock logo

Evogene NASDAQ:EVGN

$0.65 -0.05 (-7.78%)
As of 09:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Neuphoria Therapeutics stock logo

Neuphoria Therapeutics NASDAQ:NEUP

$3.81 0.00 (0.00%)
As of 09:39 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas